

转移性肾癌治疗现状和进展

依智虎

云南省文山州中医医院 云南 文山 663099

【摘要】: 20%-30%
5 10%

【关键词】:

Current status and progress in the treatment of metastatic renal cell carcinoma

Zhihu Nong

Wenshan Hospital of Traditional Chinese Medicine Yunnan Wenshan 663099

Abstract: Renal cancer is a common malignant tumor disease of the kidney, and 20%-30% of the tumors in newly diagnosed renal cancer patients have metastasized. Compared with kidney cancer, patients with metastatic kidney cancer have a higher recurrence rate and a 5-year survival rate of less than 10%. This article mainly summarizes the research progress of targeted drug therapy, immunotherapy and surgical treatment of metastatic renal cancer, in order to provide some reference for guiding the clinical treatment of metastatic renal cancer.

Keywords: Metastatic; Renal cancer; Targeted drugs; Immunotherapy

引言

1 靶向药物治疗

15.2
17.8
censor 17.8
14.3
RTKs PDGFR
VEGFR 2007
750
IFN-
31% IFN-
HIF-1 6%
IFN- 6 4
VEFF VEGFR-2 TKI
VEFF TKI
VEGFR
VEGF VEGF 5 COMPARZ
903
FLT-3 VEGFR RET PDGFR
19 117 TARGETs
AXL VEGFR-2
PFS OS PFS TKI

[7]

AVOREN IFN- VEGF CALGB 90206 IFN- VEGF IFN- mRCC 38 10007 mRCC

IFN- IFN- IFN- IFN- mRCC VEGF

mTOR mTOR mRCC RRS

RECORD- 1 TKI [2] FK 506

[3] 58 [8] RevMan5.3 11

70% 1 2 Meta

72% 53% 1 3 [9] 120

6 3 [4]

18

NSS 1 3 6 12 KPS PFS OS

2 免疫治疗 750 54 [10]

2015 CheckMate- 025

PD- 1 Motzer [9] 6- 16 2- 3

1096 PD

26

4 总结与展望

Rini [6]

参考文献:

- [1] ... VEGF sVEGFR2 [J].
,2019,0(4): 309- 313.
- [2] ... Meta [J].
,2019,40(3):171- 177.
- [3] ... [J].
29(10):855- 858.
- [4] ... [J].
,2018,33(5):355- 360.
- [5] Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med, 2018, 378(14): 1277- 1290.
- [6] Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med,2019, 380(12): 1116- 1127.
- [7] ... [J].
,2019,24(12):1048- 1048.
- [8] ... Meta [J].
,2018,30(7):870- 872.
- [9] ... [J].
,2018,028(035):116- 119.
- [10] ... [J].
,2019,34(12):933- 936.